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Mortality after kidney transplant failure: The impact of non- Kidney transplantation is the preferred method of re-
immunologic factors. nal replacement therapy for patients with end-stage renal
Background. One third of cadaveric kidney transplant recip- disease (ESRD). Compared to patients on dialysis, trans-ients suffer graft loss within five years of transplantation. Non-
plant recipients have greater survival [1], better qualityimmunologic factors that predict mortality among non-trans-
plant patients also may be potentially modifiable risk factors of life [2], and consume fewer health care resources [3].
for mortality among patients with transplant failure. Despite improvements in immunosuppression, overall pa-
Methods. Applying multivariate survival analysis to data from tient care and the increasing use of live donors, a returnthe United States Renal Data System, we determined the effect
to dialysis after transplant failure remains a commonof immunologic or transplant related factors and non-immuno-
logic factors on mortality in patients who initiated dialysis after outcome. Over one third of cadaveric kidney transplant
kidney transplant failure in the United States between April recipients suffer graft loss within five years of trans-
1995 and September 1998. plantation [3]. Patients who initiate dialysis after trans-Results. A total of 4741 patients were followed for a median
plant failure have high mortality and derive a survivalstandard deviation of 15 11 months after initiation of dialysis
advantage from repeat transplantation, but only 15% ofafter transplant failure. The majority of the 1016 (21%) deaths
were due to cardiac (36%) or infectious (17%) causes. Patients such patients will receive another transplant [4].
in the following groups had an increased risk for all-cause Traditionally, research on outcomes in kidney trans-
mortality: older patients [hazard ratio (HR)  1.04 per year,
plant recipients has focused on immunologic factors and95% confidence interval (95% CI) 1.03–1.04], women (HR 
therapies. Less attention has been paid to non-immuno-1.31, 95% CI 1.10–1.56), patients of white race (HR  1.94,
95% CI 1.32–2.84), patients with diabetes (HR  1.76, 95% logic factors, such as the complications of chronic kidney
CI 1.43–2.16), peripheral vascular disease (HR  1.94, 95% disease (CKD) and co-morbid disease, which could affect
CI 1.54–2.43), congestive heart failure (HR  1.26, 95% CI
morbidity and mortality among these patients. Through1.05–1.53), drug use (HR  2.23; 95% CI 1.08–4.60), smokers
the course of allograft loss and return to dialysis, patients(HR  1.35, 95% CI 1.01–1.81), first transplant recipients
(HR  1.32, 95% CI 1.02–1.69), and patients with a higher who experience allograft failure are re-exposed to the
glomerular filtration rate (GFR) at dialysis initiation (HR  complications of CKD. Moreover, the success of kidney
1.04 per mL/min higher, 95% CI 1.02–1.06). Those with private
transplantation has allowed nephrologists to transplantinsurance (HR  0.67, 95% CI 0.49–0.93) and higher serum
a greater number of older patients and those with aalbumin (HR  0.73 per g/dL higher, 95% CI 0.64–0.83) had
a decreased risk for all-cause mortality. Acute rejection, anti- higher burden of co-morbid disease [3]. Consequently,
body induction, donor source, duration of graft survival and the complications of CKD such as malnutrition, anemia
the maximum attained GFR during transplantation did not
and cardiovascular disease, which predict clinical out-predict all-cause mortality.
comes among “first-time” dialysis patients [5], need toConclusions. Non-immunologic factors predicted mortality
among patients with transplant failure but immunologic and be examined among those who return to dialysis after
transplant related factors did not. Prevention, early diagnosis transplant failure. Indeed, we have recently shown that
and treatment of co-morbid conditions and the complications
kidney transplant recipients who initiate dialysis afterof chronic kidney disease may improve the survival of patients
transplant failure in the United States had mean hemato-with transplant failure.
crit (27.5%) and serum albumin (3.3 g/dL) values that
were low, and not significantly different from “first-time”Key words: renal transplantation, chronic kidney disease, co-morbid
conditions, graft failure, patient survival, end-stage renal disease. dialysis patients [6]. Therefore, we determined the effect
of both immunologic or transplant related variables and
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METHODS patients with invalid USRDS identification numbers and
patients with missing or invalid transplant or dialysis re-Study population
turn dates also were excluded. In addition, patients with
All adult patients (18 years of age) were studied a Medevid record but without a matching record in the
who initiated dialysis after kidney transplant failure Patients’ standard analysis file were excluded.
for whom a new Health Care Financing Administration
(HCFA) 2728 form was completed and included in the Analytical methods and statistical analysis
1999 update of the Medical Evidence Standard Analysis Immunologic or transplant related factors and non-
File (Medevid file) of the United States Renal Data immunologic factors were described as the mean and
System (USRDS). standard deviation for continuous variables and fre-
The Medevid file contains all data from the HCFA quency for categorical variables unless otherwise indi-
2728 form. This form is completed by the dialysis or cated. The chi-square test and t test were used to compare
transplant center for all patients beginning end-stage these factors between survivors and non-survivors. Glo-
renal disease (ESRD) treatment (dialysis or transplanta- merular filtration rate (GFR) during the time of trans-
tion). For patients with transplant failure, a new 2728 plant function and at dialysis initiation was estimated
form is required only for those patients who must reapply with an equation derived from the Modification of Diet
for ESRD Medicare coverage. During the study period, in Renal Disease Study, which is based on age, gender,
most transplant recipients were eligible for ESRD Medi- race and serum creatinine level (abstract; Levey et al, J
care coverage for three years after the time of trans- Am Soc Nephrol 11:155, 2000). GFR was estimated
plantation. Therefore, the majority of the patients identi- yearly during graft survival and the highest value was
fied for inclusion in the study were patients who had graft defined as the maximum attained GFR. Body mass index
survival of greater than three years, exhausted ESRD (BMI) at the time of dialysis initiation after transplant
Medicare coverage, and were required to reapply for failure was calculated as body weight in kilograms/
ESRD Medicare coverage. (height in meters)2 (kg/m2). The duration of ESRD prior to
The 2728 form contains information on many of the transplantation was calculated as the difference between
non-immunologic factors of interest for our current study, the first ESRD service date and the date of transplan-
including patient demographics, insurance status, em- tation. Patient deaths were classified as cardiac, infec-
ployment status, co-morbid conditions, cause of ESRD, tious, malignant, cerebrovascular, miscellaneous (includ-
pre-ESRD erythropoietin use, dialysis modality and lab- ing other) and missing.
oratory information. The laboratory information is ob- Mortality from all causes, cardiac mortality and infec-
tained within 45 days of dialysis initiation and includes tious mortality were estimated from the time of dialysis
serum creatinine, blood urea nitrogen, hemoglobin, he- initiation after transplant failure with the Kaplan-Meier
matocrit, serum albumin and the dates that these tests product limit method, and group differences were tested
were obtained. Laboratory values that were not obtained with the log rank test. Cox proportional hazards regres-
within 45 days of dialysis initiation as well as missing and sion was used to determine risk factors for all cause
out of range values were excluded. Acceptable ranges for mortality. Separate Cox regression analyses for cardiac
serum albumin, hematocrit and serum creatinine were death and infectious death were performed. The effects
defined as 0.5 to 6 g/dL, 10 to 50% and 2.0 mg/dL, of immunologic or transplant related factors and non-
respectively. immunologic factors on mortality were reported as haz-
Information regarding immunologic and transplant re- ard ratios and 95% confidence intervals (95% CI), and
lated factors was obtained from the 1999 update of the were calculated from the maximum likelihood parameter
Transplant standard analysis files of the USRDS. We estimates of the corresponding variables in the Cox
studied factors that predict mortality in patients with model. The proportional hazards assumption was as-
transplant function including donor source, immunosup- sessed graphically for each categorical variable consid-
pressive medications, and acute rejection [7, 8]. In addi- ered in the Cox regression with log-log curves. Patients
tion, we included the highest glomerular filtration rate were censored at time of repeat transplantation or the
(GFR) attained during the time of transplant function end of study follow-up (Sept. 30, 1998), whichever oc-
as an index of overall transplant function. Patient death curred first. In the Cox models for cardiac and infectious
dates and the cause of patient death were obtained from death, patients were censored at the date of death if they
the 1999 update of the Patients’ standard analysis file of died from other causes and were therefore considered
the USRDS, which contained data collected in the ESRD at risk of dying of the cause of interest until that time.
Death Notification Form (HCFA-2746). All variables significant (P  0.10) in the univariate
Patients were excluded who initiated dialysis prior to analyses (Kaplan-Meier or t test) were included in the
the implementation of the new version of the HCFA 2728 Cox model for all cause mortality. Age, gender, race and
cause of ESRD were chosen a priori to be included inform in April 1995. Patients with more than one 2728 form,
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all Cox models. In addition, the duration of ESRD prior was determined for 99% of patients. Non-survivors had
a significantly lower body mass index.to transplantation and the duration of graft survival were
included in the Cox model for all cause and cardiac Pre-dialysis erythropoietin use could be determined
for 99% of the patients. Erythropoietin use was signifi-mortality despite the lack of an association with mortality
in the univariate analysis. All other variables included in cantly lower among non-survivors (Table 1). The serum
albumin at dialysis initiation was available for 67% ofthe cardiac and infectious mortality models were chosen
using the best subset selection method in SAS software all patients and for 68% of the survivors and 67% of the
non-survivors. Serum albumin was significantly lowerversion 8.1 (SAS Institute, Inc., Cary, NC, USA), which
orders models by the likelihood score for the specified among non-survivors. At dialysis initiation, hematocrit
was available for 82% of all patients and for 81% ofnumber of variables. In the Cox regression for all cause
mortality, separate hazard ratios were determined before survivors and 82% of non-survivors. The mean hemato-
crit at dialysis initiation was significantly higher amongand after one year of graft failure for the following immu-
nologic and transplant related factors; the use of antibody non-survivors. GFR at dialysis initiation could be esti-
mated for 88% of all patients and for 88% of survivorsinduction therapy, number of acute rejection episodes
and the maximum attained GFR during transplantation. and 87% of non-survivors. The mean GFR at dialysis
initiation was significantly higher among non-survivors.A separate Cox model for all cause mortality that ex-
cluded patients who died within 30 days of graft failure A comparison of immunologic and transplant related
factors between survivors and non-survivors is shown inwas performed.
No attempt to impute missing data was made. For Table 2. Non-survivors were more likely to have received
a cadaveric donor organ. The duration of graft survival,patients with missing values for categorical variables, a
category of unknown was created and these patients acute rejection, use of induction immunosuppression,
maintenance calcineurin inhibitor use and maximum at-were included in the Cox models. Patients with incom-
plete information for continuous variables were not in- tained GFR during transplantation were similar among
survivors and non-survivors.cluded in the Cox models.
Patient survival and cause of death
RESULTS
The median patient follow-up was 15  11 months.
Patient characteristics Among patients who remained on dialysis, 24% died
(987 of 4198), while 5% (29 of 543) of patients whoAmong 5170 patients who initiated dialysis after a
failed kidney transplant and had a new Medevid record received another transplant died. The estimated one,
two and three year patient mortality from all causes wasbetween April 1, 1995 and September 30, 1998, 4741
patients were included in the study. Of the 429 patients 16%, 25% and 33%, respectively. Cardiac mortality at
one, two and three years was 6%, 11% and 13%, whileexcluded from the study, 116 patients had a dialysis re-
turn date prior to April 1, 1995, 141 patients were less infectious mortality at the same time points was 3%, 5%
and 7%, respectively.than 18 years of age, 47 patients had invalid USRDS
identification numbers or duplicate Medevid files, 62 pa- Cardiac causes accounted for the majority of deaths
(36%) followed by infections (17%), cerebrovasculartients had invalid transplant dates, 25 patients had invalid
dialysis return dates and 38 patients had no record in disorders (6%) and malignancies (2%). Miscellaneous
causes accounted for 17% of all deaths with no morethe Patients’ standard analysis file. The excluded patients
were significantly younger (33  17 years vs. 43  12 than 2% of deaths attributed to any single cause. The
cause of death was unknown for 22% of the patients.years, P  0.01) and had less diabetes (12 vs. 19%, P 
0.02), but were otherwise similar to the study patients
Risk factors for all cause, cardiac and(data not shown).
infectious mortalityA comparison of non-immunologic factors between
survivors (N  3725) and non-survivors (N  1016) is The results of the Cox regression analysis for all cause
mortality are shown in Table 3. Non-immunologic factorsshown in Table 1. Non-survivors were significantly older
and more likely to be white, more likely to be first trans- that predicted all cause mortality included older age,
female gender, white race, diabetes as the cause of ESRD,plant recipients, have ESRD secondary to diabetes, have
individual co-morbid diseases, smoke and abuse alcohol. co-morbid conditions (peripheral vascular disease, con-
gestive heart failure), drug use, smoking, lack of previousNon-survivors were also less likely to have private insur-
ance and less likely to be employed. The mean duration transplantation and a higher GFR at dialysis initiation.
In addition, patients who initiated dialysis with a higherof ESRD prior to transplantation and the frequency of
preemptive transplantation (no dialysis prior to trans- serum albumin and with private only insurance had a
lower risk for all cause mortality. None of the immuno-plant) were similar among survivors and non-survivors.
Body mass index (BMI) at the time of return to dialysis logic and transplant related factors considered in the
Gill et al: Mortality after kidney transplant failure1878
Table 1. Non-immunological factors among patients with kidney transplant failure
All patientsa Non-survivors Survivors
N  4741 N  1016 N  3725 P b
Age at graft failure years 4312 5013 4212 0.01
Gender % male 59% 59% 59% 0.83
Race 0.01
White 66% 70% 65%
Black 27% 25% 27%
Other 7% 5% 8%
Number of transplants 0.01
1 72 81 70
2 or more 28 19 30
Cause of end-stage renal disease 0.01
Diabetes 19% 35% 16%
Hypertension 18% 16% 18%
Glomerular disease 32% 23% 34%
Polycystic kidney disease 5% 5% 4%
Other 26% 22% 28%
Co-morbid disease
Diabetes 22% 38% 18% 0.01
Congestive heart failure 17% 29% 14% 0.01
Ischemic heart disease 12% 22% 9% 0.01
Peripheral vascular disease 8% 17% 5% 0.01
Stroke 3% 6% 3% 0.01
Cancer 3% 5% 2% 0.01
Smoker 7% 9% 6% 0.01
Drug use 1% 1% 1% 0.83
Alcohol abuse 1% 2% 1% 0.01
Insurance 0.01
Private 32% 27% 33%
Medicare 62% 71% 60%
Medicaid 30% 29% 30%
Other 21% 25% 19%
None 3% 3% 3%
Employed (full or part time) 23% 13% 25% 0.01
Dialysis modality 0.90
Hemodialysis 74% 74% 73%
Peritoneal dialysis 14% 14% 14%
Pre-emptive transplant 12% 12% 13% 0.30
Duration of ESRD prior to transplant years 2.43.0 2.43.1 2.43.0 0.73
Body mass index kg/m2 25.17.3 24.66.6 25.27.4 0.01
Erythropoietin use 35% 32% 36% 0.01
Laboratory parameters
Serum albumin g/dL 3.30.6 3.10.6 3.40.6 0.01
Hematocrit % 27.55.9 28.36.1 27.36.1 0.01
Glomerular filtration rate mL/min/1.73 m2 8.43.9 9.74.8 8.03.7 0.01
a The number of patients in whom data was available varied slightly for different characteristics
b P calculated from the chi-square test for categorical variables or the t test for continuous variables
Cox regression (donor source, antibody induction, acute peripheral vascular disease and a low serum albumin at
dialysis initiation.rejection, duration of graft survival or maximum GFR
Figure 1 shows the Cox-adjusted survival curves forattained during graft function  or 30 mL/min/1.73
all cause mortality by co-morbid disease status. Com-m2) predicted all cause mortality. A separate model in
pared to patients without diabetes, congestive heart fail-which the patients who died within 30 days of graft failure
ure or peripheral vascular disease (curve A), patientswere excluded (N  32) yielded similar results (results
with congestive heart failure (curve B; P 0.01), patientsnot shown).
with diabetes (curve C; P  0.01), and patients withThe results of the Cox regression analyses for cardiac
peripheral vascular disease (curve D) (P  0.01) have
and infectious causes of death are shown in Table 4. significantly lower estimated survival. Figure 2 shows the
Risk factors for cardiac death included older age, white Cox-adjusted survival curves for all cause, cardiac and
race, diabetes as the cause of ESRD, peripheral vascular infectious mortality stratified by serum albumin  or
disease, congestive heart failure, lack of erythropoietin 3.5 g/dL. Patients with serum albumin 3.5 g/dL have
use prior to dialysis initiation and receipt of a cadaveric significantly higher all cause (P  0.01) and infectious
donor organ. Risk factors for infectious death included mortality (P 0.02) and non-significantly higher cardiac
mortality (P  0.10).older age, female gender, diabetes as the cause of ESRD,
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Table 2. Immunological and transplant related factors among patients initiating dialysis after kidney transplant failure
All patientsa Non-survivors Survivors
N  4741 N  1016 N  3725 P b
Year of transplant 0.01
1965–1979 4% 4% 4%
1980–1989 39% 45% 38%
1990–1998 57% 51% 58%
Donor 0.01
Cadaveric 75% 84% 73%
Live 25% 16% 27%
Duration of graft survival years 7.14.5 7.24.7 7.04.6 0.23
Acute rejection 0.56
None 40% 42% 40%
1 33% 33% 33%
2 or more 27% 25% 27%
Antibody induction 21% 17% 22% 0.10
Maintenance calcineurin inhibitor 97% 98% 96% 0.20
Maximum GFR attained during transplantc mL/min/1.73 m2 51.537.0 50.124.7 51.841.0 0.28
a The number of patients in whom data was available varied for different characteristics
b P calculated from the chi-square test for categorical variables or the t test for continuous variables
c GFR (glomerular filtration rate) was estimated yearly during graft survival and the highest value was defined as the maximum attained GFR
Table 3. Predictors of all cause mortality after kidney transplant failurea (Cox multivariate regression)
Hazard ratio 95% CI P
Age at graft failure per year higher 1.04 1.03–1.04 0.01
Female gender 1.31 1.10–1.56 0.01
Race reference other
White 1.94 1.32–2.84 0.01
Black 1.45 0.96–2.17 0.08
Cause of ESRD reference glomerulonephritis
Diabetes 1.76 1.43–2.16 0.01
Polycystic kidney disease 0.85 0.57–1.26 0.42
Other 1.01 0.82–1.25 0.93
Peripheral vascular disease 1.94 1.54–2.43 0.01
Congestive heart failure 1.26 1.05–1.53 0.01
Drug use 2.23 1.08–4.60 0.03
Smoking 1.35 1.01–1.81 0.04
Number of transplants ref 2
One 1.32 1.02–1.69 0.03
Unknown 0.79 0.55–1.14 0.22
Insurance reference neither Medicare or private
Private only 0.67 0.49–0.93 0.02
Medicare only 1.06 0.83–1.35 0.64
Both Medicare and private 0.99 0.74–1.36 0.43
GFR at dialysis initiation per mL/min higher 1.04 1.02–1.06 0.01
Serum albumin at dialysis initiation per g/dL higher 0.73 0.64–0.83 0.01
a Significant variables P  0.05 shown. Other variables included in the Cox model are: duration of ESRD prior to transplant, duration of graft survival, co-morbid
conditions at return to dialysis (ischemic heart disease, stroke, cancer), history of alcohol abuse, employment status, obesity at return to dialysis (BMI 30 kg/m2),
hematocrit at dialysis initiation, pre-dialysis erythropoietin use, donor type, antibody induction, number of acute rejections, and maximum glomerular filtration rate
attained during transplant ( or 30 mL/min).
DISCUSSION plantation) did not predict all-cause mortality. Preven-
tion, early diagnosis and treatment of non-immunologicThe estimated two-year mortality rate among patients
factors may improve outcomes among these patients.with transplant failure in our study was 25% and is simi-
In comparison to the patients in this study, the esti-lar to that reported in other studies [4]. Mortality from
mated two year mortality among similarly aged “first-all causes was predicted by non-immunologic factors in-
time” dialysis patients is 20%, while the estimated twocluding co-morbid conditions (diabetes, peripheral vas-
year mortality among first cadaveric transplant recipientscular disease, congestive heart failure) smoking, drug
with graft function is 6% [3]. The aim of our study wasuse and low serum albumin levels. In contrast immuno-
to determine the impact of non-immunologic and immu-logic and transplant related factors (donor source, immu-
nologic or transplant related factors on patient survivalnosuppressive medications, acute rejection, duration of
graft survival, maximum attained GFR during trans- and not to compare the survival of patients with trans-
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Table 4. Predictors of cardiac and infectious death after kidney transplant failurea (Cox multivariate regression)
Hazard ratio 95% CI P
Cardiac death
Age at graft failure per year older 1.03 1.02–1.05 0.01
Race reference other
White 2.27 1.19–4.35 0.01
Black 1.43 0.72–2.83 0.30
Cause of ESRD reference glomerulonephritis
Diabetes 1.75 1.27–2.42 0.01
Polycystic kidney disease 0.81 0.44–1.50 0.50
Other 0.89 0.63–1.26 0.50
Peripheral vascular disease 1.80 1.26–2.59 0.01
Congestive heart failure 1.40 1.04–1.90 0.03
Erythropoietin use prior to transplant failure 0.74 0.56–0.99 0.04
Donor type reference live donor
Cadaveric 1.60 1.03–2.52 0.04
Unknown donor 1.73 0.93–3.21 0.08
Infectious death
Age at transplant failure per year higher 1.03 1.02–1.05 0.01
Female gender 1.48 1.01–2.16 0.04
Cause of ESRD reference glomerulonephritis
Diabetes 2.17 1.37–3.42 0.01
Polycystic disease 1.60 0.76–3.38 0.22
Other 0.90 0.52–1.55 0.14
Peripheral vascular disease 2.01 1.21–3.33 0.01
Albumin at dialysis initiation per g/dL higher 0.64 0.48–0.86 0.01
a Significant variables P  0.05 shown. Other variables in the Cox regression for cardiac death are: gender, co-morbid conditions (ischemic heart disease, stroke),
smoking, duration of ESRD prior to transplant, duration of graft survival, type of insurance, number of transplants, glomerular filtration rate, albumin and hematocrit
at dialysis initiation. Other variables in the Cox regression for infectious death are race, and glomerular filtration rate at dialysis initiation.
Fig. 1. Adjusted all-cause mortality. (A) Pa-
tients without diabetes, congestive heart fail-
ure or peripheral vascular disease, (B) patients
with congestive heart failure, (C) patients
with diabetes, (D) patients with peripheral
vascular disease. Compared to patients with-
out co-morbid conditions (A), patients with
congestive heart failure (P  0.01), diabetes
(P  0.01) and peripheral vascular disease
(P 0.01) have lower estimated survival (Cox
regression model censored at repeat trans-
plantation).
plant failure to that of other patient groups. Therefore, exposure to non-traditional risk factors [10]. In this re-
gard, patients with transplant failure are exposed to bothdefinitive conclusions regarding the comparative survival
of patients with transplant failure cannot be made. Nev- non-traditional CKD related cardiovascular risk factors
such as elevated serum creatinine and proteinuria [11]ertheless, given the relatively young age and low burden
of co-morbid disease in this cohort of ESRD patients, we and non-traditional transplant related cardiovascular risk
factors such as immunosuppressive medications [9]. Thebelieve that the mortality among patients with transplant
failure is unacceptably high. cumulative exposure to these non-traditional cardiovas-
cular risk factors may underlie the cardiac mortality inThe finding that cardiac disease accounted for the ma-
jority of deaths is consistent with findings from studies these patients.
Although the clinical management of co-morbid con-in patients with functioning transplants and patients on
dialysis [3, 7, 9]. The high prevalence of cardiovascular ditions was not assessed in our study, co-morbid condi-
tions are under-treated among dialysis and transplantdisease among patients with CKD is in part related to
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Fig. 2. Adjusted all-cause (A), cardiac (B)
and infectious (C ) mortality by serum albumin
level  or 3.5 g/dL (Cox regression model
censored at repeat transplantation).
patients [12, 13]. A number of factors unique to the opathy [16], respectively. Fragmentation of patient care
and lack of communication between care providers dur-transplant population may directly or indirectly impede
the clinical management of co-morbid conditions. Prior ing the transition from transplantation to dialysis may
be additional important barriers to the provision of ag-to dialysis initiation, efforts to preserve allograft function
may take precedence over other clinical management gressive co-morbid disease management [17]. Finally,
the lack of proven efficacy of treatment of co-morbidissues, resulting in under-diagnosis and under-treatment
of co-morbid conditions. Sub-optimal treatment of car- conditions in this population as well as the perception
that transplant recipients are a relatively healthy cohortdiovascular conditions may result from under utilization
of ACE inhibitors, erythropoietin and HMG CoA reduc- of ESRD patients may lead to complacency about the
treatment of co-morbid conditions.tase inhibitors due to concerns of worsened allograft
function [14], hypertension [15], and statin-induced my- We determined the effect of complications of CKD
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(anemia, hypoalbuminemia) on mortality, and found hypertension and the chronic exposure to immunosup-
pressive medications on mortality, the duration of graftthat patients with low serum albumin at dialysis initiation
had a higher risk for all-cause and infectious mortality. survival was included as an independent variable in the
Cox regression model for all-cause mortality. This vari-Low serum albumin has been previously identified as a
risk factor for mortality among patients with graft func- able also was chosen to account for improvements in
transplantation that have occurred over time [19]. Thesetion [18]. The strong association between serum albumin
level and mortality in this study demonstrates that serum immunologic and transplant related factors were not risk
factors for all-cause mortality. We believe that becausealbumin is a useful tool to identify high-risk patients.
Whether nutritional and non-nutritional interventions of the long duration of graft survival among patients in
our study, risk factors related to the transplant procedurecan improve serum albumin levels among these patients,
and whether an improvement in serum albumin can lead may no longer be relevant for patient survival after graft
failure. The patients in this cohort had a mean durationto reduced mortality remains to be seen. In univariate
analysis, non-survivors had a significantly higher hemato- of graft survival of seven years and therefore these find-
ings may not apply to patients with a shorter durationcrit at the time of dialysis initiation compared to survi-
vors. However, the hematocrit level at dialysis initiation of graft survival.
The higher relative risk for all-cause mortality amongwas not associated with survival in any of the multivariate
analyses. Given the fact that hematocrit levels may fluc- females has not previously been reported. In a study of
19,000 patients with allograft failure, Ojo and colleaguestuate rapidly, a single hematocrit measurement at the
time of dialysis initiation may not accurately reflect the reported a higher risk for mortality among male patients
[4]. Compared to that study, our study included patientsexposure to anemia before and after graft failure. Studies
with longitudinal hematocrit measurements during the who had returned to dialysis after a much longer duration
of graft survival (median 74 vs. 17 months in the studyprogression of graft dysfunction and after graft failure
are needed to determine the possible association of he- by Ojo et al). A higher death rate among male patients
with graft function [7] may have resulted in a survivalmatocrit level and mortality.
We also determined the association of the level of bias for those males who returned to dialysis after a long
duration of graft survival in our study. In addition, ourresidual renal function (estimated GFR) at the time of
dialysis initiation and pre-dialysis erythropoietin use study included information regarding many co-morbid
diseases for which males may be at higher risk (ischemicwith mortality because we believe these factors may be
surrogates of the quality of delivered CKD care. The heart disease, congestive heart failure, stroke, peripheral
vascular disease). Indeed, the prevalence of peripheralfinding that patients who initiated dialysis at higher levels
of GFR had an increased risk for all-cause mortality is vascular disease (8.0% for males vs. 6.0% for females,
P  0.03) and ischemic heart disease (13% for males vs.counterintuitive. We believe that this finding reflects the
fact that the sickest patients tend to require dialysis initi- 10% for females, P  0.01) was higher among males in
this study. In studies that did not include these co-morbidation at higher levels of residual renal function. The
finding that patients who received pre-dialysis erythro- conditions, the higher mortality risk among males may
represent male gender acting as a surrogate for thesepoietin were at decreased risk for cardiac mortality is
consistent with our hypothesis that this variable may and other unmeasured co-morbid conditions.
Patients with private insurance had a decreased riskreflect the quality of delivered CKD care. We previously
reported that 66% of patients in this cohort who received for all cause mortality relative to patients who had nei-
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